Observations placeholder
Belsomra and Suvorexant
Identifier
023949
Type of Spiritual Experience
Number of hallucinations: 181
Background
A description of the experience
Suvorexant, sold under the trade name Belsomra, is a medication for the treatment of insomnia.
Suvorexant is a selective, dual orexin receptor antagonist . It was approved for sale by the U.S. Food and Drug Administration (FDA) on August 13, 2014. The U.S. Drug Enforcement Administration (DEA) has placed it on the list of schedule IV controlled substances, as it may lead to limited physical dependence or psychological dependence relative to the drugs or other substances in schedule III. The potential for psychological dependence is similar to that of zolpidem. The drug became available in Japan in November 2014 and in the United States in February 2015.
Most common Belsomra side effects from eHealthme
- Drug ineffective - (1,219 reports)
- Nightmares - (371 reports)
- Abnormal dreams - (320 reports)
- Drowsiness - (260 reports)
- Headache - (225 reports)
- Feeling abnormal - (215 reports)
- Insomnia - (175 reports)
- Hallucinations - (171 reports)
- Sleep paralysis - (112 reports)
- Dizziness - (102 reports)